Duration of Antibiotic Therapy in Acute Kidney Graft Pyelonephritis (AGPN): Effect on the Risk of Recurrence

N/AActive Not RecruitingNCT06848816

Central Hospital, Nancy, France500 enrolled

Overview

The aim of this study is to evaluate the impact of the duration of antibiotic therapy on the risk of recurrence in kidney graft pyelonephritis. The secondary objectives are to identify the factors associated with the duration of antibiotic therapy in acute kidney graft pyelonephritis, identify the factors associated with recurrence of acute kidney graft pyelonephritis within 3 months, evaluate the impact of the duration of antibiotic therapy on antibiotic-related complications and assess the impact of the duration of antibiotic therapy on the progression of renal function after acute kidney graft pyelonephritis.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Pyelonephritis Acute Kidney Transplantation Recipients

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients * Kidney transplant recipients with a functional graft. * Hospitalization with acute pyelonephritis (APN) defined by fever OR chills (noted in the clinical records) AND bacteriuria AND exclusion of another obvious cause of fever. (For rehospitalizations, also include cases where antibiotic therapy was initiated based on suspicion, even in the absence of documented infection.) Exclusion Criteria: * Age \< 18 years. * Vacationing patient or lost to follow-up with follow-up \< 3 months.

Locations (1)

Outcomes

Primary Outcomes

Relaspe AGPN

Rehospitalization for acute kidney graft pyelonephritis (AGPN) within three months after completion of treatment

Time frame: 3 month

Secondary Outcomes

Early AGPN relapse

Rehospitalization for acute kidney graft pyelonephritis (AGPN) within one month after completion of treatment

Time frame: 1 month

ITU relapse

Antibiotic treatment for urinary tract infection within 3 months after completion of treatment.

Time frame: 3 month

Identical microorganism relapsing AGPN

New episode of AGPN with the same pathogen within 3 months after completion of treatment

Time frame: 3 month

Multidrug resistant emerging pathogens

Infection with a multidrug-resistant bacteria within 3 months after completion of treatment

Time frame: 3 month

Clostridioides difficile colitis

Occurrence of Clostridioides difficile colitis within 3 months after completion of treatment

Time frame: 3 month

Early kidney function evolution

Evolution of renal function (creatininemia) 1 month after completion of treatment for APNAG.

Time frame: 1 month

3 month kidney function evolution

Evolution of renal function (creatininemia) 3 +/- 21 days after completion of treatment for AGPN

Time frame: 3 month and 21 days

Risk factors

Clinical and biological Factors associated with AGPN recurrence independently of the duration of antibiotic therapy

Time frame: 3 month